Thymosin α1 protects from CTLA-4 intestinal immunopathology

The advent of immune checkpoint inhibitors has represented a major boost in cancer therapy, but safety concerns are increasingly being recognized. Indeed, although beneficial at the tumor site, unlocking a safeguard mechanism of the immune response may trigger autoimmune-like effects at the peripher...

Descripción completa

Detalles Bibliográficos
Autores principales: Renga, Giorgia, Bellet, Marina M, Pariano, Marilena, Gargaro, Marco, Stincardini, Claudia, D’Onofrio, Fiorella, Mosci, Paolo, Brancorsini, Stefano, Bartoli, Andrea, Goldstein, Allan L, Garaci, Enrico, Romani, Luigina, Costantini, Claudio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Life Science Alliance LLC 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7441522/
https://www.ncbi.nlm.nih.gov/pubmed/32817121
http://dx.doi.org/10.26508/lsa.202000662

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7441522/
https://www.ncbi.nlm.nih.gov/pubmed/32817121
http://dx.doi.org/10.26508/lsa.202000662

Ejemplares similares